MedPath

The Ablate-by-LAW Study

Not Applicable
Completed
Conditions
Atrial Fibrillation
Interventions
Procedure: Personalized atrial fibrillation ablation
Registration Number
NCT04218604
Lead Sponsor
Centro Medico Teknon
Brief Summary

Of all the determinants of lesion creation during atrial fibrillation (AF) ablation, left atrial wall thickness (LAWT), as measured with multi-detector cardiac tomography (MDCT) is one key element that has been evaluated in some retrospective analyses but is not yet used per protocol to modulate the radiofrequency delivery. Adapting ablation index (AI) to LAWT would be very useful in standardising the ablation procedure with parameters fitted to every patient, enabling the development of a personalized approach that will both: i) increase efficacy by performing transmural lesions to prevent the formation of conduction gaps in the initial lesion set, and ii) increase safety by preventing excessive RF delivery on thin wall areas related to procedural complications, such as cardiac perforation or atrio-esophageal fistula. The investigators sought to evaluate the feasibility, safety, efficacy and reproducibility of guiding AF ablation procedures with the integrated MDCT-derived LAWT information.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
106
Inclusion Criteria
  • Age > 18 years.
  • Indication for paroxysmal atrial fibrillation ablation.
  • Signed informed consent.
Exclusion Criteria
  • Age < 18 years.
  • Pregnancy.
  • Previous AF ablation procedure (REDO).

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Personalized AF ablation using MDCT-derived LAWTPersonalized atrial fibrillation ablationPre-procedural MDCT images will be analysed in Teknon Medical Center (core-lab), using ADAS-3D™ (Galgo Medical, Barcelona, Spain) to obtain 3D atrial wall thickness maps that will be introduced into CARTO® navigation system (Biosense Webster, Diamond Bar, California, US). PVI will be performed point-by-point, aiming to complete a RF circle around the PV ostia (nephroid shape) on the 3D geometry using a ThermoCool® SmartTouch® 3.5-mm irrigated tip contact force-sensing RF ablation catheter (Biosense Webster, Inc.). AI targets will be defined by LAWT on the thickness color map, as follows: Thickness \< 1 mm (red): 300; 1-2 mm (yellow): 350; 2-3 mm (green): 400; 3-4 mm (blue): 450; \> 4 mm (purple): 500. The recommended power settings to reach these AI values will be, in general, 35 W for the posterior wall and 40 W for the anterior wall. Wherever local AWT is \> 3 mm (green and blue colors), an increased RF power (50 W) will be permitted.
Primary Outcome Measures
NameTimeMethod
Arrhythmia-free survival1 year

1-year atrial arrhythmia-free survival

Secondary Outcome Measures
NameTimeMethod
Peri-procedural complications1 month
Acute procedural outcomes1 day

Procedure times

REDO outcomes2 years

Mean LAWT at late reconnection sites

Trial Locations

Locations (5)

Heart Center Leipzig University Hospital

🇩🇪

Leipzig, Germany

Herz- und Diabeteszentrum Nordrhein-Westfalen

🇩🇪

Bad Oeynhausen, Germany

Azienda Ospedaliero-Universitaria Pisana

🇮🇹

Pisa, Italy

Teknon Medical Center

🇪🇸

Barcelona, Spain

Puerta del Mar University Hospital

🇪🇸

Cadiz, Spain

© Copyright 2025. All Rights Reserved by MedPath